001     276324
005     20250314091251.0
024 7 _ |a 10.1111/ene.16562
|2 doi
024 7 _ |a pmid:39878395
|2 pmid
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a altmetric:173681251
|2 altmetric
037 _ _ |a DZNE-2025-00287
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Alefanti, Ioanna
|b 0
245 _ _ |a The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease.
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738752355_12998
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) SNCA pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population.Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G-positive samples underwent haplotype analysis.We identified 10 additional p.A30G-positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33-62) and a broad spectrum of non-motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations.These findings underscore that the p.A30G SNCA pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the SNCA gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a SNCA
|2 Other
650 _ 7 |a Greek population
|2 Other
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a p.A30G
|2 Other
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a SNCA protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a alpha-Synuclein: genetics
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a Greece
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Pedigree
|2 MeSH
650 _ 2 |a Haplotypes
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease: genetics
|2 MeSH
700 1 _ |a Koros, Christos
|0 0000-0001-5806-0717
|b 1
700 1 _ |a Tsami, Viktoria
|b 2
700 1 _ |a Simitsi, Athina Maria
|b 3
700 1 _ |a Kartanou, Chrisoula
|b 4
700 1 _ |a Papagiannakis, Nikolaos
|b 5
700 1 _ |a Bozi, Maria
|b 6
700 1 _ |a Antonelou, Roubina
|b 7
700 1 _ |a Maniati, Matina
|b 8
700 1 _ |a Hauser, Ann-Kathrin
|0 P:(DE-2719)2351249
|b 9
|u dzne
700 1 _ |a Varvaressos, Stefanos
|b 10
700 1 _ |a Bonakis, Anastasios
|b 11
700 1 _ |a Lourentzos, Konstantinos
|b 12
700 1 _ |a Makrythanasis, Periklis
|b 13
700 1 _ |a Papageorgiou, Sokratis G
|b 14
700 1 _ |a Proukakis, Christos
|b 15
700 1 _ |a Potagas, Constantinos
|b 16
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 17
|u dzne
700 1 _ |a Koutsis, Georgios
|b 18
700 1 _ |a Karadima, Georgia
|b 19
700 1 _ |a Stefanis, Leonidas
|b 20
773 _ _ |a 10.1111/ene.16562
|g Vol. 32, no. 2, p. e16562
|0 PERI:(DE-600)2020241-6
|n 2
|p e16562
|t European journal of neurology
|v 32
|y 2025
|x 1351-5101
856 4 _ |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276324/files/DZNE-2025-00287.pdf
856 4 _ |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276324/files/DZNE-2025-00287.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276324
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2351249
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2320009
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2022
|d 2024-12-12
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-12
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)1240005
|k ICRU
|l Core ICRU
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1240005
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21